Lumican Peptides: Rational Design Targeting ALK5/TGFBRI

Area of Science:

• Extracellular matrix biology
• Ophthalmology
• Peptide therapeutics

Background:

• Lumican, a small leucine-rich proteoglycan (SLRP), is crucial for maintaining corneal transparency and homeostasis.
• Lumican regulates collagen fibrillogenesis and corneal epithelial wound healing.
• A C-terminal peptide of lumican (LumC13) has shown potential in promoting wound healing via ALK5 receptor interaction.

Purpose of the Study:

• To elucidate the mechanism of LumC13 binding to ALK5/TGFBR1.
• To identify the minimal amino acid sequence required for stable LumC13-ALK5 complex formation.
• To validate the therapeutic potential of LumC13 and its derivatives in corneal wound healing.

Main Methods:

• In silico investigation of LumC13 derivatives binding to ALK5.
• In vitro assessment of peptide efficacy on corneal epithelial cell migration.
• In vivo evaluation of peptide-induced corneal wound healing.

Main Results:

• LumC13 forms a stable complex with ALK5.
• Computational modeling identified key amino acids for LumC13-ALK5 interaction.
• Tested LumC13 derivatives demonstrated significant promotion of corneal epithelial cell migration and wound healing in vivo.

Conclusions:

• LumC13 (Lumikine) is a therapeutically valuable peptide for promoting corneal epithelial wound healing.
• The study validates a computational approach for designing receptor-binding peptides.
• Findings support the clinical relevance of LumC13 for treating corneal debridement injuries.